

**MARKSANS PHARMA LIMITED**

Regd. Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri [West], Mumbai-400053

**UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2011**

Rs.in Lacs

Sr. No.	PARTICULARS	For the quarter ended on		For the period ended on		For the year ended on
		30.9.2011 (UNAUDITED)	30.9.2010 (UNAUDITED)	30.9.2011 (UNAUDITED)	30.9.2010 (UNAUDITED)	31st March 11 (AUDITED)
1	Income					
	a> Net Sales/ Income from Operations	5,001.77	4,473.96	8,300.92	8,650.47	15,543.76
	b> Other Operating Income	50.58	7.28	53.21	36.68	168.64
	<b>Total Income</b>	<b>5,052.35</b>	<b>4,481.24</b>	<b>8,354.13</b>	<b>8,687.15</b>	<b>15,712.40</b>
2	Expenditure					
	a> (Increase)/Decrease in stock in trade	0.14	244.77	(2.02)	(4.66)	3.55
	b> Consumption of Material & Purchases	2,266.82	2,713.10	4,110.74	5,756.64	10,728.29
	c> Employee Cost	309.20	229.68	622.21	524.62	1,137.68
	d> Depreciation	1,410.01	148.67	1,723.93	394.65	1,464.39
	e> Other Expenditure	997.80	439.26	1,607.75	793.59	5,074.43
	<b>Total Expenditure</b>	<b>4,983.97</b>	<b>3,775.47</b>	<b>8,062.61</b>	<b>7,464.83</b>	<b>18,408.34</b>
3	Profit from Operations before other income, Interest & Exceptional Items (1-2)	68.38	705.77	291.52	1,222.32	(2,695.94)
4	Other Income	-	-	-	-	-
5	Profit before Interest & Exceptional item (3+4)	68.38	705.77	291.52	1,222.32	(2,695.94)
6	Interest	286.36	499.80	539.59	895.36	10,576.67
7	Profit after Interest but before Tax & Exceptional items	(217.98)	205.97	(248.07)	326.96	(13,272.61)
8	Exceptional items	-	-	-	-	-
9	<b>Profit/(Loss) from Ordinary activities before Tax (7+8)</b>	<b>(217.98)</b>	<b>205.97</b>	<b>(248.07)</b>	<b>326.96</b>	<b>(13,272.61)</b>
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	-	-	-	-	484.63
11	<b>Net Profit/(Loss) from Ordinary activities after tax(9-10)</b>	<b>(217.98)</b>	<b>205.97</b>	<b>(248.07)</b>	<b>326.96</b>	<b>(13,757.24)</b>
	Less: Extraordinary Item-(Loss)/Profit on sale of division/Fixed assets	-	(8,112.22)	-	(8,112.22)	(8,021.68)
13	<b>Net Profit/ (Loss) for the period (11-12)</b>	<b>(217.98)</b>	<b>(7,906.25)</b>	<b>(248.07)</b>	<b>(7,785.26)</b>	<b>(21,778.92)</b>
14	Paid up Equity Share Capital (Face Value Re. 1 each)	3,678.07	3,678.07	3,678.07	3,678.07	3,678.07
15	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year	-	-	-	-	6,031.23
16	a> Earnings Per Share (Basic & Diluted) (before extraordinary items.Rs.)	(0.06)	0.06	(0.07)	0.09	(3.74)
	b> Earnings Per Share( Basic & Diluted) (after Extraordinary items- Rs.)	(0.06)	(2.15)	(0.07)	(2.12)	(5.92)
17	Aggregate of Public Shareholding:					
	- Number of Shares	189,823,694	189,823,694	189,823,694	189,823,694	189,823,694
	- Percentage of Holding	51.61%	51.61%	51.61%	51.61%	51.61%
18	Promoters and Promoter group Shareholdings	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510
	a> Pledged/Encumbered					
	- Number of Shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N.A	N.A	N.A	N.A	N.A
	- Percentage of Holding (as a % of the total share capital of the Company)	N.A	N.A	N.A	N.A	N.A
	a> Non-encumbered					
	- Number of Shares	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%
	- Percentage of Holding (as a % of the total share capital of the Company)	48.39%	48.39%	48.39%	48.39%	48.39%



**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.11.2011.
- 2 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 3 As reported earlier, the outstanding of principal value of Foreign Currency Convertible Bonds(The Bonds) of USD 43,999,000, which have become due for redemption with redemption premium of USD 19,887,548, has not been redeemed.  
The Company has provided the aforesaid liabilities in the books of accounts. As on 30.09.2011, the Company has not made Provision for foreign exchange fluctuation with respect to the aforesaid Bonds for the current year.
- 4 The Company is making necessary compliances under the provisions of Section 15 of the Sick Industrial Companies (Special Provisions) Act, 1985.
- 5 Pursuant to the Special Resoluion passed by the shareholders of the Company, the Board of Directors of the Company has, at its meeting held on 25th October, 2011, issued and allotted 1,75,00,000 Warrants (convertible into equal number of equity shares of Re. 1/- each face value) at a price of Rs. 2.56 per warrant to Mr. Mark Saldanha (Promoter Group) on preferential allotment basis in accordance with Chapter VII of the SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2009.
- 6 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 7 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- 8 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- 9 Statement of Assets and Liabilities


(Rs. In Lakhs)

Particulars	YEAR ENDED	YEAR ENDED
	30.09.2011	30.09.2010
	UNAUDITED	UNAUDITED
<b>SHAREHOLDERS FUND:</b>		
(a) Capital	5,028.07	5,028.07
(b) Reserve and Surplus	6,031.23	6,031.23
<b>LOAN FUNDS</b>	40,763.14	31,114.18
<b>FIXED ASSETS</b>	17,109.17	22,303.30
<b>INVESTMENTS</b>	6,761.64	6,761.64
<b>CURRENT ASSETS , LOANS AND ADVANCES</b>		
(A) Inventories	4,005.61	4,055.71
(B) Sundry Debtors	8,486.59	7,171.16
(c ) Cash and Bank balance	3,034.01	2,387.08
(d) Other current assets		
(e) Loans and Advances	2,743.06	2,730.80
<b>Less: Current Liabilities and Provisions</b>		
(a) Liabilities and provision	4,344.06	3,386.25
Deferred Tax Assets/(Liability) (Net)	(1,496.14)	(1,150.00)
<b>MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)</b>	1.31	20.52
<b>PROFIT AND LOSS ACCOUNT</b>	(15,521.25)	(1,279.53)

For MARKSANS PHARMA LIMITED



MARK SALDANHA  
Managing Director.



Place: Mumbai.

Date: 14.11.2011

Visit us at [www.marksanspharma.com](http://www.marksanspharma.com)

**Notes:**

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 14.11.11
- 2 The Consolidated Financial Statements Include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- 3 The Consolidated Financial Statements are prepared in accordance with Accounting Standard 21 "Consolidated Financial Statement" issued by the Institute of Chartered Accountants of India.
- 4 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 5 As reported earlier, the outstanding of principal value of Foreign Currency Convertible Bonds(The Bonds) of USD 43,999,000, which have become due for redemption with redemption premium of USD 19,887,548, has not been redeemed. The Company has provided the aforesaid liabilities in the books of accounts. As on 30.09.2011, the Company has not made Provision for foreign exchange fluctuation with respect to the aforesaid Bonds for the current year.
- 6 The Company is making necessary compliances under the provisions of Section 15 of the Sick Industrial Companies (Special Provisions) Act, 1985.
- 7 Pursuant to the Special Resoluion passed by the shareholders of the Company, the Board of Directors of the Company has, at its meeting held on 25th October, 2011, issued and allotted 1,75,00,000 Warrants (convertible into equal number of equity shares of Re. 1/- each face value) at a price of Rs. 2.56 per warrant to Mr. Mark Saldanha (Promoter Group) on preferential allotment basis in accordance with Chapter VII of the SEBI (Issue of Capital and Disclosure Requirement) Regulations, 2009.
- 8 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- 9 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 10 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- 11 Statement of Assets and Liabilities

(Rs. In Lakhs)

Particulars	YEAR ENDED	YEAR ENDED
	30.09.2011	30.09.2010
	UNAUDITED	UNAUDITED
<b>SHAREHOLDERS FUND:</b>		
(a) Capital	5,028.07	5,028.07
(b) Reserve and Surplus	5,908.29	6,312.09
<b>LOAN FUNDS</b>	48,996.00	38,413.09
Minority Interest	303.51	128.08
<b>FIXED ASSETS</b>	26,815.23	32,211.33
<b>INVESTMENTS</b>	-	-
<b>CURRENT ASSETS, LOANS AND ADVANCES</b>		
(A) Inventories	7,257.69	6,026.61
(B) Sundry Debtors	11,750.57	10,195.62
(c) Cash and Bank balance	3,231.83	2,416.19
(d) Other current assets		
(e) Loans and Advances	2,825.51	2,795.63
<b>Less: Current Liabilities and Provisions</b>		
(a) Liabilities and provision	8,075.66	5,948.59
Deferred Tax Assets/(Liability) (Net)	(1,581.87)	(1,228.47)
<b>MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJL)</b>	1.31	20.52
<b>PROFIT AND LOSS ACCOUNT</b>	(18,011.26)	(3,392.50)

For MARKSANS PHARMA LIMITED


  
**MARK SALDANHA**  
 Managing Director.


Place: Mumbai.

Date: 14.11.11

Visit us at [www.marksanspharma.com](http://www.marksanspharma.com)

**MARKSANS PHARMA LIMITED**

Regd. Office: 11th Floor, Lotus Business Park, Off. New Link Road, Andheri (West), Mumbai-400053

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2011**

Rs.in Lacs

Sr. No.	PARTICULARS	For the quarter ended on		For the period ended on		For the year ended on
		30.9.2011 (UNAUDITED)	30.9.2010 (UNAUDITED)	30.9.2011 (UNAUDITED)	30.9.2010 (UNAUDITED)	31st March 11 (AUDITED)
1	Income					
	a>. Net Sales/ Income from Operations	9,799.63	8,079.49	17,153.27	15,284.35	30,531.80
	b>. Other Operating Income	52.12	8.55	57.32	39.69	175.06
	<b>Total Income</b>	<b>9,851.75</b>	<b>8,088.04</b>	<b>17,210.59</b>	<b>15,324.04</b>	<b>30,706.86</b>
2	Expenditure					
	a>. ( Increase)/Decrease in stock in trade	0.14	411.00	(2.02)	203.38	(45.33)
	b>. Consumption of Material & Purchases	5,381.03	4,894.73	9,907.50	9,924.60	20,324.89
	c>. Employee Cost	1,026.71	820.37	2,058.33	1,630.36	3,625.61
	d>. Depreciation	1,444.70	178.53	1,793.36	455.90	1,997.52
	e>. Other Expenditure	1,693.71	1,014.30	2,856.54	1,793.16	7,306.31
	<b>Total Expenditure</b>	<b>9,546.29</b>	<b>7,318.93</b>	<b>16,613.71</b>	<b>14,007.41</b>	<b>33,209.00</b>
3	Profit from Operations before other income, Interest & Exceptional Items (1-2)	305.46	769.11	596.88	1,316.63	(2,502.14)
4	Other Income	-	-	-	-	-
5	Profit before Interest & Exceptional item (3+4)	305.46	769.11	596.88	1,316.63	(2,502.14)
6	Interest	381.14	671.22	719.45	1,133.71	11,020.56
7	Profit after Interest but before Tax & Exceptional items	(75.68)	97.89	(122.57)	182.92	(13,522.70)
8	Exceptional items	-	-	-	-	-
9	<b>Profit/(Loss) from Ordinary activities before Tax (7+8)</b>	<b>(75.68)</b>	<b>97.89</b>	<b>(122.57)</b>	<b>182.92</b>	<b>(13,522.70)</b>
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	-	(2.08)	-	-	641.36
11	<b>Net Profit/(Loss) from Ordinary activities after tax(9-10)</b>	<b>(75.68)</b>	<b>99.97</b>	<b>(122.57)</b>	<b>182.92</b>	<b>(14,164.06)</b>
12	a>. Less::- Minority Interest	18.62	29.22	68.04	31.16	138.71
	b>. Less: Extraordinary Item-(Loss)/Profit on sale of division/Fixed assets	-	(8,112.22)	-	(8,112.22)	(8,021.68)
13	<b>Net Profit/ (Loss) for the period (11-12)</b>	<b>(94.30)</b>	<b>(8,041.48)</b>	<b>(190.61)</b>	<b>(7,960.46)</b>	<b>(22,324.45)</b>
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.07	3,678.07	3,678.07	3,678.07	3,678.07
15	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year	-	-	-	-	6,216.30
16	a>. Earnings Per Share (Basic & Diluted) (before extraordinary items.Rs.)	(0.02)	0.03	(0.03)	0.05	(3.85)
	b>. Earnings Per Share( Basic & Diluted) (after Extraordinary items- Rs.)	(0.03)	(2.19)	(0.05)	(2.16)	(6.07)
17	Aggregate of Public Shareholding:	-	-	-	-	-
	- Number of Shares	189,823,694	189,823,694	189,823,694.00	189,823,694.00	189,823,694
	- Percentage of Holding	51.61%	51.61%	51.61%	51.61%	51.61%
18	Promoters and Promoter group Shareholdings	177,983,510	177,983,510	177,983,510.00	177,983,510.00	177,983,510
	a>. Pledged/Encumbered	-	-	-	-	-
	- Number of Shares	NIL	NIL	NIL	NIL	NIL
	- Percentage of Holding	N.A	N.A	N.A	N.A	N.A
	(as a % of the total shareholding of Promoter and Promoter Group)					
	- Percentage of Holding	N.A	N.A	N.A	N.A	N.A
	(as a % of the total share capital of the Company)					
	a>. Non-encumbered	-	-	-	-	-
	- Number of Shares	177,983,510	177,983,510	177,983,510.00	177,983,510.00	177,983,510
	- Percentage of Holding	100%	100%	100%	100%	100%
	(as a % of the total shareholding of Promoter and Promoter Group)					
	- Percentage of Holding	48.39%	48.39%	48.39%	48.39%	48.39%
	(as a % of the total share capital of the Company)					

Sr. No.	PARTICULARS	For the quarter ended on		For the period ended on		For the year ended on
		30.9.2011 (UNAUDITED)	30.9.2010 (UNAUDITED)	30.9.2011 (UNAUDITED)	30.9.2010 (UNAUDITED)	31st March 11 (AUDITED)
	Revenue	5,052.35	4,481.24	8,354.13	8,687.15	15,712.40
	Profit Before Tax from Ordinary activities	(217.98)	205.97	(248.07)	326.96	(13,272.61)
	Profit After Tax from Ordinary activities	(217.98)	205.97	(248.07)	326.96	(13,757.24)
	Profit After Tax after extraordinary item	(217.98)	(7,906.25)	(248.07)	(7,785.26)	(21,778.92)